DrugBiological
Sibeprenlimab clinical trials
Also written VIS649.
- studies test it
- 9
- open now
- 5
- in phase 3
- 4
- first study started
- 2018
Keep track of what changes. Save the sibeprenlimab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Development codes
Studies by the year they started
9 studies that test it; most in 2022 (3)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2022 | 3 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 2
- Phase 2
- 4
- Phase 3
- 4
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 9 · Other 0
Otsuka Pharmaceutical Development & Commercialization, Inc. (7) · Otsuka Beijing Research Institute (1) · Vertex Pharmaceuticals Incorporated (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses sibeprenlimab is read from its arms, and is right about nine times in ten.
Testing it · 9
- A Phase 3b Study of Participant Experience on Povetacicept Administered Via Autoinjector as Compared to Sibeprenlimab Administered Via Prefilled SyringeNot yet recruitingPhase 3Vertex Pharmaceuticals IncorporatedNCT07890909Written as Sibeprenlimab
- Trial of Sibeprenlimab in Children and Adolescents With Immunoglobulin A Nephropathy (IgAN)Not yet recruitingPhase 3Otsuka Pharmaceutical Development & Commercialization, Inc.NCT07770815Written as Sibeprenlimab
- A Study to Evaluate the Effectiveness and Safety of Sibeprenlimab in Participants With Primary Membranous Nephropathy, Immune-mediated Focal Segmental Glomerulosclerosis, and Minimal Change DiseaseNot yet recruitingPhase 2Otsuka Pharmaceutical Development & Commercialization, Inc.NCT07861113Written as Sibeprenlimab
- Trial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy (IgAN)Enrolling by invitationPhase 2/3Otsuka Pharmaceutical Development & Commercialization, Inc.NCT05248659Written as Sibeprenlimab 400 mg s.c. Q4weeks
- Trial of the Impact of Sibeprenlimab on Immunoglobulin A Nephropathy Kidney TissueRecruitingPhase 2Otsuka Pharmaceutical Development & Commercialization, Inc.NCT06740526Written as Sibeprenlimab
- Trial of Sibeprenlimab in the Treatment of A Nephropathy (IgAN)Active, not recruitingPhase 3Otsuka Pharmaceutical Development & Commercialization, Inc.NCT05248646Written as Sibeprenlimab 400 mg
- First in Human Study to Assess Safety of VIS649 in Healthy SubjectsCompletedPhase 1Otsuka Pharmaceutical Development & Commercialization, Inc.NCT03719443Written as VIS649
- A Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Participants With Sjögren'sActive, not recruitingPhase 2Otsuka Pharmaceutical Development & Commercialization, Inc.NCT06928142Written as Sibeprenlimab
- Safety and Tolerability, and PK of Sibeprenlimab in Chinese Healthy SubjectCompletedPhase 1Otsuka Beijing Research InstituteNCT07105124Written as Sibeprenlimab
Codes
What other systems call sibeprenlimab · ClinicalTrials.gg INT002181
- MeSH (NLM) C000731962sibeprenlimabOne source NLM
- UNII (FDA) GHX28QZ7DDSIBEPRENLIMABConfirmed FDA, NLM
- NCI Thesaurus C179120SibeprenlimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000731962 | sibeprenlimab | One source NLM |
| UNII (FDA) | GHX28QZ7DD | SIBEPRENLIMAB | Confirmed FDA, NLM |
| NCI Thesaurus | C179120 | Sibeprenlimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.